Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis

Journal of Clinical Oncology

Volumn 33, Issue 7, 2015, Pages 773-781

  Teulings, Hansje Eva ^a,c   Limpens, Jacqueline ^a   Jansen, Sophia N ^a   Zwinderman, Aeilko H ^a   Reitsma, Johannes B ^a,b   Spuls, Phyllis I ^a   Luiten, Rosalie M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Department of Dermatology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CELL THERAPY AGENT; IMMUNOMODULATING AGENT; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IMMUNOSTIMULATION; INCIDENCE; MELANOMA; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMATIC REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; VITILIGO; CANCER STAGING; DISEASE FREE SURVIVAL; HYPOPIGMENTATION; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROGNOSIS; RISK; SKIN NEOPLASMS;

DISEASE-FREE SURVIVAL; HUMANS; HYPOPIGMENTATION; IMMUNOTHERAPY; INCIDENCE; KAPLAN-MEIER ESTIMATE; MELANOMA; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; SKIN NEOPLASMS; VITILIGO;

EID: 84925326818     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.4756     Document Type: Article

References (149)

1. Attia P, Phan GQ, Maker AV, et al: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053, 2005
2. Beck KE, Blansfield JA, Tran KQ, et al: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283-2289, 2006
3. Downey SG, Klapper JA, Smith FO, et al: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTLassociated antigen-4 blockade. Clin Cancer Res 13: 6681-6688, 2007
4. Gogas H, Ioannovich J, Dafni U, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718, 2006
5. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003
6. Weber JS, O'Day S, Urba W, et al: Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26:5950-5956, 2008
7. Boasberg PD, Hoon DS, Piro LD, et al: Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 126:2658-2663, 2006
8. Bystryn JC, Rigel D, Friedman RJ, et al: Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 123:1053-1055, 1987
9. Rosenberg SA, White DE: Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 19:81-84, 1996
10. Scheibenbogen C, Hunstein W, Keilholz U: Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 30A:1209-1211, 1994
11. Quaglino P, Marenco F, Osella-Abate S, et al: Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: Results from a single-institution hospital-based observational cohort study. Ann Oncol 21:409-414, 2010
12. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002
13. Luiten RM, Kueter EW, Mooi W, et al: Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 23:8978-8991, 2005
14. Nordlund JJ, Kirkwood JM, Forget BM, et al: Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 9:689-696, 1983
15. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
16. Gogas H, Eggermont AM, Hauschild A, et al: Biomarkers in melanoma. Ann Oncol 20 Suppl 6:vi8-13, 2009
17. Riley RD, Sauerbrei W, Altman DG: Prognostic markers in cancer: The evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 100:1219-1229, 2009
18. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
19. Tarhini AA, Cherian J, Moschos SJ, et al: Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 30:322-328, 2012
20. Telang S, Rasku MA, Clem AL, et al: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer 11:515, 2011
21. Weide B, Derhovanessian E, Pflugfelder A, et al: High response rate after intratumoral treatment with interleukin-2: Results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116:4139-4146, 2010
22. Rasku MA, Clem AL, Telang S, et al: Transient T cell depletion causes regression of melanoma metastases. J Transl Med 6:12, 2008
23. Satzger I, Meier A, Schenck F, et al: Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 121:2562-2566, 2007
24. Pashenkov M, Goess G, Wagner C, et al: Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24:5716-5724, 2006
25. Eton O, Rosenblum MG, Legha SS, et al: Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer 95:127-134, 2002
26. O'Day SJ, Boasberg PD, Piro L, et al: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 8:2775-2781, 2002
27. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001
28. Bajetta E, Del Vecchio M, Mortarini R, et al: Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4:75-85, 1998
29. Aarntzen EH, De Vries IJ, Lesterhuis WJ, et al: Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell -based vaccination. Cancer Res 73:19-29, 2013
30. Russo V, Pilla L, Lunghi F, et al: Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer 132:2557-2566, 2013
31. Hunger RE, Kernland LK, Markowski CJ, et al: Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunother 60:1553-1564, 2011
32. Adamina M, Rosenthal R, Weber WP, et al: Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Molecular Therapy 18:651-659, 2010
33. Baba T, Sato-Matsushita M, Kanamoto A, et al: Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A∗2402. J Transl Med 8:84, 2010
34. Bedikian AY, Richards J, Kharkevitch D, et al: A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 20:218-226, 2010
35. Dangoor A, Lorigan P, Keilholz U, et al: Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose polyepitope vaccine. Cancer Immunol Immunother 59: 863-873, 2010
36. Eton O, Ross MI, East MJ, et al: Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med 8:9, 2010
37. Ginsberg BA, Gallardo HF, Rasalan TS, et al: Immunologic response to xenogeneic gp100 DNA in melanoma patients: Comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res 16:4057-4065, 2010
38. Jacobs JFM, Punt CJA, Lesterhuis WJ, et al: Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: A phase I/II study in metastatic melanoma patients. Clin Cancer Res 16:5067-5078, 2010
39. Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, et al: Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2. Actas Dermosifiliogr 100:571-585, 2009
40. Lienard D, Avril MF, Le Gal FA, et al: Vaccination of melanoma patients with Melan-A/Mart-1 peptide and klebsiella outer membrane protein P40 as an adjuvant. J Immunother 32:875-883, 2009
41. Yuan J, Ku GY, Gallardo HF, et al: Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 9:5, 2009
42. Butterfield LH, Comin-Anduix B, Vujanovic L, et al: Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 31:294-309, 2008
43. Daud AI, DeConti RC, Andrews S, et al: Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26:5896-5903, 2008
44. von Euw EM, Barrio MM, Furman D, et al: A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells: Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med 6:6, 2008
45. Osorio M, Gracia E, Rodriguez E, et al: Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: Results of a Phase Ib/IIa study. Cancer Biol Ther 7:488-495, 2008
46. Perales MA, Yuan J, Powel S, et al: Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 16:2022-2029, 2008
47. Slingluff CL Jr, Petroni GR, Olson W, et al: Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 26:4973-4980, 2008
48. Dillman RO, DePriest C, DeLeon C, et al: Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 22:309-321, 2007
49. Guo J, Zhu J, Sheng X, et al: Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer 120:2418-2425, 2007
50. Hamid O, Solomon JC, Scotland R, et al: Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: Correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 13:215-222, 2007
51. Lesimple T, Neidhard EM, Vignard V, et al: Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res 12:7380-7388, 2006
52. Melanoma Study Group of the Mayo Clinic Cancer Center, Celis E: Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: Evidence of systemic immune dysfunction. Cancer 110:203-214, 2007
53. Powell DJ Jr, Felipe-Silva A, Merino MJ, et al: Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 179:4919-4928, 2007
54. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al: Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13:6386-6395, 2007
55. Kaufman HL, Cohen S, Cheung K, et al: Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther 17:239-244, 2006
56. Kyte JA, Mu L, Aamdal S, et al: Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13:905-918, 2006
57. Lindsey KR, Gritz L, Sherry R, et al: Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res 12: 2526-2537, 2006
58. Palucka AK, Ueno H, Connolly J, et al: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29:545-557, 2006
59. Ridolfi R, Petrini M, Fiammenghi L, et al: Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med 4:36, 2006
60. Salcedo M, Bercovici N, Taylor R, et al: Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 55:819-829, 2006
61. Seledtsov VI, Shishkov AA, Surovtseva MA, et al: Xenovaccinotherapy for melanoma. Eur J Dermatol 16:655-661, 2006
62. Wei Y, Sticca RP, Holmes LM, et al: Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 28:585-593, 2006
63. Yagi H, Hashizume H, Horibe T, et al: Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 66:10136-10144, 2006
64. Akiyama Y, Tanosaki R, Inoue N, et al: Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med 3:4, 2005
65. Chianese-Bullock KA, Woodson EM, Tao H, et al: Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother 28:412-419, 2005
66. Escobar A, Lopez M, Serrano A, et al: Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 142:555-568, 2005
67. Escudier B, Dorval T, Chaput N, et al: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of the first phase 1 clinical trial. J Transl Med 3:10, 2005
68. Heinzerling L, Burg G, Dummer R, et al: Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: Clinical efficacy. Hum Gene Ther 16:35-48, 2005
69. Kaufman HL, DeRaffele G, Mitcham J, et al: Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 115:1903-1912, 2005
70. Triozzi PL, Aldrich W, Allen KO, et al: Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother 28:382-388, 2005
71. Triozzi PL, Strong TV, Bucy RP, et al: Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther 16:91-100, 2005
72. Chapman PB, Wu D, Ragupathi G, et al: Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 10:4717-4723, 2004
73. Guthmann MD, Bitton RJ, Carnero AJ, et al: Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: A report on safety and immunogenicity. J Immunother 27:442-451, 2004
74. Haenssle HA, Krause SW, Emmert S, et al: Hybrid cell vaccination in metastatic melanoma: Clinical and immunologic results of a phase I/II study. J Immunother 27:147-155, 2004
75. Hersey P, Menzies SW, Halliday GM, et al: Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53:125-134, 2004
76. Di NM, Carlo-Stella C, Mortarini R, et al: Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: A phase I trial in metastatic melanoma. Clin Cancer Res 10:5381-5390, 2004
77. Ribas A, Glaspy JA, Lee Y, et al: Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27:354-367, 2004
78. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al: Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22:4474-4485, 2004
79. Trefzer U, Herberth G, Wohlan K, et al: Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 110:730-740, 2004
80. Vilella R, Benítez D, Milá J, et al: Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother 53:651-658, 2004
81. Astsaturov I, Petrella T, Bagriacik EU, et al: Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: Implications for cancer vaccines. Clin Cancer Res 9:4347-4355, 2003
82. Butterfield LH, Ribas A, Dissette VB, et al: Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998-1008, 2003
83. Nagayama H, Sato K, Morishita M, et al: Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 13:521-530, 2003
84. Phan GQ, Touloukian CE, Yang JC, et al: Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 26:349-356, 2003
85. Pullarkat V, Lee PP, Scotland R, et al: A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 9:1301-1312, 2003
86. Ragupathi G, Livingston PO, Hood C, et al: Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 9:5214-5220, 2003
87. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al: Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colonystimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016-4026, 2003
88. Smithers M, O'Connell K, MacFadyen S, et al: Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 52:41-52, 2003
89. Soiffer R, Hodi FS, Haluska F, et al: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21:3343-3350, 2003
90. Tagawa ST, Lee P, Snively J, et al: Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 98:144-154, 2003
91. Krause SW, Neumann C, Soruri A, et al: The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 25:421-428, 2002
92. Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451-6458, 2001
93. Dillman RO, DeLeon C, Beutel LD, et al: Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol 39:115-123, 2001
94. Gajewski TF, Fallarino F, Ashikari A, et al: Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 7:895s-901s, 2001
95. Lee P, Wang F, Kuniyoshi J, et al: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 19:3836-3847, 2001
96. Slingluff CL Jr, Yamshchikov G, Neese P, et al: Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Cancer Res 7:3012-3024, 2001
97. Mackensen A, Herbst B, Chen JL, et al: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385-392, 2000
98. Osanto S, Schiphorst PP, Weijl NI, et al: Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum Gene Ther 11:739-750, 2000
99. Trefzer U, Weingart G, Chen Y, et al: Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma. Int J Cancer 85:618-626, 2000
100. Palmer K, Moore J, Everard M, et al: Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther 10:1261-1268, 1999
101. Schreiber S, Kampgen E, Wagner E, et al: Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study. Hum Gene Ther 10:983-993, 1999
102. Wang F, Bade E, Kuniyoshi C, et al: Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 5:2756-2765, 1999
103. Chakraborty NG, Sporn JR, Tortora AF, et al: Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 47:58-64, 1998
104. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332, 1998
105. Soiffer R, Lynch T, Mihm M, et al: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colonystimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 95:13141-13146, 1998
106. Sun Y, Jurgovsky K, Möller P, et al: Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study. Gene Ther 5:481-490, 1998
107. Stopeck AT, Hersh EM, Akporiaye ET, et al: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15:341-349, 1997
108. Jaeger E, Bernhard H, Romero P, et al: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66:162-169, 1996
109. Nabel GJ, Gordon D, Bishop DK, et al: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 93:15388-15393, 1996
110. Delyon J, Mateus C, Lefeuvre D, et al: Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil countsis associated with improved survival. Ann Oncol 24: 1697-1703, 2013
111. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013
112. Queirolo P, Morabito A, Laurent S, et al: Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: A pilot study. Cancer Invest 31:336-345, 2013
113. Voskens CJ, Goldinger SM, Loquai C, et al: The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the Ipilimumab Network. PLoS ONE 8:e53745, 2013
114. Wilgenhof S, Four SD, Vandenbroucke F, et al: Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 36:215-222, 2013
115. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
116. Berthe A, Roussel A, Quereux G, et al: Study of a cohort of patients with metastatic melanoma treated with ipilimumab[in French]. Pharmacien Hospitalier et Clinicien 48:77-87, 2013
117. Ribas A, Chesney JA, Gordon MS, et al: Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med 10:236, 2012
118. Margolin K, Ernstoff MS, Hamid O, et al: Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 13:459-465, 2012
119. Farolfi A, Ridolfi L, Guidoboni M, et al: Ipilimumab in advanced melanoma: Reports of longlasting responses. Melanoma Res 22:263-270, 2012
120. Sarnaik AA, Yu B, Yu D, et al: Extended dose ipilimumab with a peptide vaccine: Immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 17:896-906, 2011
121. Bronstein Y, Ng CS, Hwu P, et al: Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. Amer J Roentgen 197: W992-W1000, 2011
122. Kirkwood JM, Lorigan P, Hersey P, et al: Phase II trial of tremelimumab (CP-675206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16:1042-1048, 2010
123. Ku GY, Yuan J, Page DB, et al: Singleinstitution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival. Cancer 116:1767-1775, 2010
124. Camacho LH, Antonia S, Sosman J, et al: Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27:1075-1081, 2009
125. Ribas A, Comin-Anduix B, Chmielowski B, et al: Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267-6276, 2009
126. Weber J, Thompson JA, Hamid O, et al: A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591-5598, 2009
127. Downey SG, Klapper JA, Smith FO, et al: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13: 6681-6688, 2007
128. Straatsma BR, Nusinowitz S, Young TA, et al: Surveillance of the eye and vision in clinical trials of CP-675206 for metastatic melanoma. Am J Ophthalmol 143:958-969, 2007
129. Maker AV, Yang JC, Sherry RM, et al: Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29:455-463, 2006
130. Maker AV, Phan GQ, Attia P, et al: Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 12:1005-1016, 2005
131. Reuben JM, Lee BN, Li C, et al: Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106:2437-2444, 2006
132. Sanderson K, Scotland R, Lee P, et al: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23:741-750, 200
133. Pilon-Thomas S, Kuhn L, Ellwanger S, et al: Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35:615-620, 2012
134. Verdegaal EM, Visser M, Ramwadhdoebe TH, et al: Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother 60:953-963, 2011
135. Besser MJ, Shapira-Frommer R, Treves AJ, et al: Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16:2646-2655, 2010
136. Besser MJ, Shapira-Frommer R, Treves AJ, et al: Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lymphodepleting chemotherapy regimen in metastatic melanoma patients. J Immunother 32:415-423, 2009
137. Khammari A, Labarrière N, Vignard V, et al: Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol 129:2835-2842, 2009
138. Wallen H, Thompson JA, Reilly JZ, et al: Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS ONE 4:e4749, 2009
139. Dudley ME, Yang JC, Sherry R, et al: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239, 2008
140. Powell DJ Jr, de Vries CR, Allen T et al: Inability to mediate prolonged reduction of regulatory T cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J Immunother 30:438-447, 2007
141. Duval L, Schmidt H, Kaltoft K, et al: Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: A phase I trial in metastatic melanoma. Clin Cancer Res 12:1229-1236, 2006
142. Mackensen A, Meidenbauer N, Vogl S, et al: Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24:5060-5069, 2006
143. Powell DJ Jr, Dudley ME, Hogan KA, et al: Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 177:6527-6539, 2006
144. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357, 2005
145. Ridolfi L, Ridolfi R, Riccobon A, et al: Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma. J Immunother 26:156-162, 2003
146. Yee C, Thompson JA, Byrd D, et al: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99:16168-16173, 2002
147. Lau R, Wang F, Jeffery G, et al: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66-78, 2001
148. Teulings HE, Overkamp M, Ceylan E, et al: Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: A survey among 1,307 patients and their partners. Br J Dermatol 168:162-171, 2013
149. Weber JS, Dummer R, de Pril V, et al: Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119: 1675-1682, 2013